Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/18/2018
Start Date:March 6, 2015

Use our guide to learn which trials are right for you!

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

This randomized phase II trial studies how well tamoxifen citrate works compared with
z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby
tissue or lymph nodes or other parts of the body and has estrogen receptors but not human
epidermal growth factor receptor 2 (HER2) receptors on the surface of its cells. Estrogen can
cause the growth of tumor cells. Hormone therapy using tamoxifen citrate or z-endoxifen
hydrochloride may fight breast cancer by lowering the amount of estrogen the body makes. It
is not yet known whether tamoxifen citrate or z-endoxifen hydrochloride is more effective in
treating patients with breast cancer.

PRIMARY OBJECTIVES:

I. To assess whether progression-free survival with z-endoxifen hydrochloride (HCl) relative
to that with tamoxifen (tamoxifen citrate) is prolonged in postmenopausal women with local
advanced or metastatic estrogen receptor (ER) positive/Her2 negative breast cancer.

SECONDARY OBJECTIVES:

I. To assess the safety profile of each of these agents in this patient population.

II. To assess whether the tumor response rate (as determined using the Response Evaluation
Criteria in Solid Tumors [RECIST] criteria) among those randomized to z-endoxifen HCl differs
from that among those randomized to tamoxifen.

III. To estimate the median progression-free survival time for those who receive z-endoxifen
HCl after disease progression with tamoxifen.

TERTIARY OBJECTIVES:

I. To examine whether ER alpha alterations (defined as either ER activating mutations or ER
amplification) are associated with longer progression-free survival (PFS) or higher response
rates in the z-endoxifen HCl arm compared to the tamoxifen arm.

II. To determine changes in lipid profiles comparing tamoxifen and z-endoxifen HCl.

III. For each treatment, to evaluate changes in markers of bone formation and absorption
after 12 weeks (4 cycles) of treatment.

IV. For all patients and by treatment arm, to determine whether progression-free survival
differs with respect to the sensitive to endocrine therapy (SET) index.

V. To examine whether deoxyribonucleic acid (DNA) alterations as measured by Foundation
medicine in all coding exons of 287 cancer-related genes as well as 78 polymorphisms in 34
absorption, distribution, metabolism, and excretion (ADME)-related genes are associated with
longer PFS or higher response rates in the z-endoxifen HCl arm compared to the tamoxifen arm.

VI. To assess whether the molecular characteristics identified in the tumor biopsies are
detectable in the circulating tumor cells (CTCs) and/or cell-free DNA (cfDNA).

VII. For each treatment arm: to examine changes in ER expression on CTCs, changes in estrogen
receptor (ESR) mutations or amplification in CTCs or CfDNA and explore the impact of these
changes on PFS and response rates.

VIII. To further characterize pharmacokinetics, pharmacogenetics and metabolism of
z-endoxifen HCl and tamoxifen.

IX. To determine the impact of the concentrations of tamoxifen and its metabolites on PFS in
the tamoxifen arm.

X. To determine the impact of the concentrations of z-endoxifen HCl and its metabolites on
PFS in the endoxifen arm.

XI. To determine the impact of genetic variation in the enzymes responsible for tamoxifen and
z-endoxifen HCl metabolism.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive z-endoxifen hydrochloride orally (PO) on days 1-21. Courses repeat
every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive tamoxifen citrate PO once daily (QD) on days 1-21. Courses repeat
every 21 days in the absence of disease progression or unacceptable toxicity. Patients with
disease progression and bone metastases may cross over to Arm I and receive z-endoxifen
hydrochloride starting no later than 28 days after documentation of disease progression.

After completion of study treatment, patients are followed up yearly for up to 5 years.

Inclusion Criteria:

- PRE-REGISTRATION ELIGIBILITY CRITERIA

- Women who agree to undergo a standard of care core biopsy of recurrent or metastatic
breast cancer to confirm the ER+ (>= 10% nuclear staining) and HER2 negative status

- Patient must have been previously treated with an aromatase inhibitor (either
letrozole, anastrozole or exemestane) either in the adjuvant or metastatic setting,
and have one of the following types of primary or secondary endocrine resistant
disease

- Primary clinical resistance is defined as one of the following:

- Recurrence within the first 2 years of adjuvant endocrine therapy while on
aromatase inhibitor therapy

- Progression within first 6 months of initiating first-line endocrine therapy
(either aromatase inhibitor or fulvestrant containing regimen) for the
treatment of metastatic breast cancer

- Secondary clinical resistance is defined as one of the following:

- Recurrence after year 2 while receiving adjuvant aromatase inhibitor
therapy, or within 12 months of completing adjuvant aromatase inhibitor
therapy

- Progression occurring 6 or more months after initiating the first endocrine
therapy for metastatic disease (either fulvestrant or aromatase inhibitor
containing regimen)

- Patients with a history of measurable disease as defined by RECIST criteria or bone
only disease are eligible; Note: those patients with non-measurable disease and bone
metastases are eligible

- No history of tumors involving spinal cord or heart

- No current evidence of visceral crisis or lymphangitic spread

- No known brain metastases

- Women must be postmenopausal

- Postmenopausal status is verified by:

- Prior bilateral surgical oophorectomy, or

- Age >= 60 years, or

- Age < 60 with no menses for > 1 year with follicle-stimulating hormone (FSH)
and estradiol levels within post menopausal range, according to
institutional standard

- Prior treatment

- No more than two prior chemotherapy regimens in the metastatic setting

- Prior treatment with an aromatase inhibitor (either anastrozole, letrozole or
exemestane), either in the adjuvant or metastatic setting is required

- Unlimited prior endocrine regimens in the metastatic setting, which may have
included an everolimus or cyclin dependent kinase (CDK) 4/6 inhibitor (such as
palbociclib, abemaciclib or ribociclib) containing regimen

- Prior tamoxifen treatment is allowed in the adjuvant setting, but patients must
not have experienced relapse within 1 year of stopping tamoxifen

- No prior treatment with tamoxifen in the metastatic setting

- No prior treatment with endoxifen

- Patients who have not fully recovered from acute, reversible effects of prior
therapy regardless of interval since last treatment are not eligible to
participate in this study

- EXCEPTION: neuropathies-if grade 2 neuropathies have been stable for at
least 3 months since completion of prior treatment patient is eligible

- Not receiving any medications or substances that are strong inhibitors of cytochrome
P450 family 2, subfamily D, polypeptide 6 (CYP2D6)

- Not receiving any other investigational agents

- No uncontrolled intercurrent illness including, but not limited to:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Uncontrolled symptomatic cardiac arrhythmia

- Uncontrolled hypertension (defined as blood pressure > 160/90)

- None of the following co-morbid conditions:

- Cataracts of grade 2 or greater as per Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0

- Retinopathy of grade 2 or greater as per CTCAE version 4.0

- Note: patients that have cataracts that do not require surgery are eligible

- Note: serious adverse events will be reported on CTEP-Adverse Event
Reporting System (AERS) using CTCAE version (v)5.0

- Deep vein thrombosis/pulmonary embolism (DVT/PE) within the past 6 months

- Note: patients that are on anticoagulant therapy for maintenance are
eligible as long as the DVT and/or PE occurred > 6 months prior to
enrollment, and there is no evidence for active thrombosis (either DVT or
PE)

- No other active second malignancy other than non-melanoma skin cancers within 3 years
of pre-registration; a second malignancy is not considered active if all treatment for
that malignancy is completed and the patient has been disease-free for at least 3
years prior to pre-registration

- Eastern Cooperative Oncology Group (ECOG) performance status: 0-2

- Able to swallow oral formulation of the study agent

- Hemoglobin >= 9 g/dL

- Platelet count >= 75,000/mm^3

- Creatinine =< 1.5 x upper limits of normal (ULN)

- Total bilirubin =< 1.5 x upper limits of normal (ULN)

- Aspartate aminotransferase (AST) =< 2.5 x upper limits of normal (ULN); for patients
with liver metastasis: =< 5 x upper limits of normal (ULN)

- REGISTRATION ELIGIBILITY CRITERIA

- Patients with either measurable disease as defined by RECIST criteria or bone only
disease are eligible; Note: those patients with both non-measurable disease and bone
metastases are eligible

- Non-measurable bone only disease: Non-measurable bone only disease may include
any of the following: blastic bone lesions, lytic bone lesions without a
measurable soft-tissue component, or mixed lytic-blastic bone lesions without a
measurable soft-tissue component

- Lytic bone lesions, with an identifiable soft tissue component, evaluated by
computed tomography (CT) or magnetic resonance imaging (MRI), can be considered
as measurable lesions if the soft tissue component otherwise meets the definition
of measurability previously described

- No tumors involving spinal cord or heart

- No visceral crisis, lymphangitic spread or known brain metastases: visceral crisis is
not the mere presence of visceral metastases, but implies severe organ dysfunction as
assessed by symptoms and signs, laboratory studies, and rapid progression of disease

- Histologic confirmation, from the A011203 pre-registration biopsy, by
institutional/local pathologist of either locally advanced or metastatic breast cancer
that is estrogen receptor positive and HER2 negative; those patients with bone only
disease with either no tumor or insufficient tumor for ER/progesterone receptor (PR)
and HER2 staining after the bone biopsy are still eligible to participate in this
study

- Estrogen receptor positive disease is defined as > 10% nuclear staining

- HER2 negative disease as per 2013 American Society of Clinical Oncology (ASCO)/College
of American Pathologists (CAP) guidelines, one of the following must apply:

- 0 or 1+ by immunohistochemistry (IHC) and not amplified by in situ hybridization
(ISH)

- 0 or 1+ by IHC and ISH not done

- 2+ by IHC and not amplified by ISH or

- IHC not done and not amplified by ISH

- None of the following therapies are allowed prior to registration:

- Chemotherapy =< 2 weeks

- Immunotherapy =< 2 weeks

- Biologic therapy =< 2 weeks

- Hormonal therapy =< 2 weeks

- Monoclonal antibodies =< 2 weeks

- Radiation therapy =< 2 weeks

- Anti-Her-2 or other "targeted" (e.g. mammalian target of rapamycin [mTOR])
therapy =< 2 weeks

- NOTE : Any toxicities derived from these therapies must be =< grade 2 prior
to starting study therapy
We found this trial at
569
sites
Fairbanks, Alaska 99701
Principal Investigator: John A. Keech
Phone: 253-403-2394
?
mi
from
Fairbanks, AK
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
?
mi
from
Augusta, ME
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Barbara S. Craft
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
701 Doctors Dr
Kinston, North Carolina 28504
(252) 559-2200
Principal Investigator: Peter R. Watson
Phone: 252-559-2200
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
?
mi
from
Kinston, NC
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Seattle, WA
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
?
mi
from
Yakima, WA
Click here to add this to my saved trials
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
?
mi
from
Akron, OH
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 855-774-5433
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
?
mi
from
Athens, GA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Amelia B. Zelnak
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-403-2394
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
?
mi
from
Augusta, GA
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 800-446-5532
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
?
mi
from
Bainbridge Island, WA
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Helen K. Chew
Phone: 916-734-3089
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
?
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 800-821-7532
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: John T. Cole
Phone: 888-562-4763
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 253-403-2394
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellevue, Washington 98005
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
?
mi
from
Belmont, NC
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 614-488-2745
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
1300 Anne Street NW
Bemidji, Minnesota 56601
(218) 751-5430
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Bend, OR
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Boise, ID
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Boone, IA
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
?
mi
from
Brainerd, MN
Click here to add this to my saved trials
Branson, Missouri 65616
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
?
mi
from
Brewer, ME
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Brooklyn, New York 11203
Principal Investigator: Iuliana Shapira
Phone: 718-613-8324
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Mehmet S. Copur
Phone: 800-998-2119
?
mi
from
Burien, WA
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
?
mi
from
Burlingame, CA
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
?
mi
from
Cameron Park, CA
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
?
mi
from
Canton, MI
Click here to add this to my saved trials
Canton, Ohio 44708
Principal Investigator: Mitchell Haut
Phone: 888-293-4673
?
mi
from
Canton, OH
Click here to add this to my saved trials
2600 Sixth St. SW
Canton, Ohio 44710
330.363.4908
Principal Investigator: Shruti Trehan
Phone: 330-363-6891
Aultman Health Foundation The Aultman Foundation will raise and administer funds in order to support...
?
mi
from
Canton, OH
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: James L. Wade
Phone: 217-876-4740
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: James L. Wade
Phone: 217-876-4740
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-4673
?
mi
from
Caro, MI
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: James L. Wade
Phone: 217-876-4740
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Cary, North Carolina 27511
Principal Investigator: Mark L. Graham
Phone: 919-233-8585
?
mi
from
Cary, NC
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Eunpi Cho
Phone: 415-209-2686
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials